ID: ALA3909213

Max Phase: Preclinical

Molecular Formula: C31H39N7O3

Molecular Weight: 557.70

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cc(C)c(CNC(=O)c2cc(-c3cnc(N4CCNCC4)nc3)cc3c2C(C)CN3C2CCOCC2)c(=O)[nH]1

Standard InChI:  InChI=1S/C31H39N7O3/c1-19-12-21(3)36-30(40)26(19)17-33-29(39)25-13-22(23-15-34-31(35-16-23)37-8-6-32-7-9-37)14-27-28(25)20(2)18-38(27)24-4-10-41-11-5-24/h12-16,20,24,32H,4-11,17-18H2,1-3H3,(H,33,39)(H,36,40)

Standard InChI Key:  YPAORUYRBZFOFV-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 557.70

Molecular Weight (Monoisotopic): 557.3114

AlogP: 2.89

#Rotatable Bonds: 6

Polar Surface Area: 115.48

Molecular Species: BASE

HBA: 8

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.64

CX Basic pKa: 8.69

CX LogP: 1.59

CX LogD: 0.28

Aromatic Rings: 3

Heavy Atoms: 41

QED Weighted: 0.42

Np Likeness Score: -1.03

References

1. Ansari A, Satalkar S, Patil V, Shete AS, Kaur S, Gupta A, Singh S, Raja M, Severance DL, Bernales S, Chakravarty S, Hung DT, Pham SM, Herrera FJ, Rai R..  (2017)  Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.,  27  (2): [PMID:27923618] [10.1016/j.bmcl.2016.11.080]

2. Ansari A, Satalkar S, Patil V, Shete AS, Kaur S, Gupta A, Singh S, Raja M, Severance DL, Bernales S, Chakravarty S, Hung DT, Pham SM, Herrera FJ, Rai R..  (2017)  Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.,  27  (2): [PMID:27923618] [10.1016/j.bmcl.2016.11.080]

Source

Source(1):

• Scientific Literature